American Association for Cancer Research
15417786mcr130111-sup-fig2.pdf (233.43 kB)

Supplementary Figure 2 from A Novel Germline Mutation in BAP1 Predisposes to Familial Clear-Cell Renal Cell Carcinoma

Download (233.43 kB)
journal contribution
posted on 2023-04-03, 16:04 authored by Megan N. Farley, Laura S. Schmidt, Jessica L. Mester, Samuel Peña-Llopis, Andrea Pavia-Jimenez, Alana Christie, Cathy D. Vocke, Christopher J. Ricketts, James Peterson, Lindsay Middelton, Lisa Kinch, Nick Grishin, Maria J. Merino, Adam R. Metwalli, Chao Xing, Xian-Jin Xie, Patricia L.M. Dahia, Charis Eng, W. Marston Linehan, James Brugarolas

PDF file - 233K, VHL mutation status in some but not all tumors from Family NCI-1326.



Renal cell carcinoma (RCC) clusters in some families. Familial RCC arises from mutations in several genes, including the von Hippel-Lindau (VHL) tumor suppressor, which is also mutated in sporadic RCC. However, a significant percentage of familial RCC remains unexplained. Recently, we discovered that the BRCA1-associated protein-1 (BAP1) gene is mutated in sporadic RCC. The BAP1 gene encodes a nuclear deubiquitinase and appears to be a classic two-hit tumor suppressor gene. Somatic BAP1 mutations are associated with high-grade, clear-cell RCC (ccRCC) and poor patient outcomes. To determine whether BAP1 predisposes to familial RCC, the BAP1 gene was sequenced in 83 unrelated probands with unexplained familial RCC. Interestingly, a novel variant (c.41T>A; p.L14H) was uncovered that cosegregated with the RCC phenotype. The p.L14H variant targets a highly conserved residue in the catalytic domain, which is frequently targeted by missense mutations. The family with the novel BAP1 variant was characterized by early-onset ccRCC, occasionally of high Fuhrman grade, and lacked other features that typify VHL syndrome. These findings suggest that BAP1 is an early-onset familial RCC predisposing gene.Implications:BAP1 mutations may drive tumor development in a subset of patients with inherited renal cell cancer. Mol Cancer Res; 11(9); 1061–71. ©2013 AACR.

Usage metrics

    Molecular Cancer Research



    Ref. manager